Market Overview:
The global relapsing multiple sclerosis treatment market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing incidence of MS, rising awareness about available treatments, and technological advancements in MS treatment. The global relapsing multiple sclerosis treatment market is segmented on the basis of type into immunomodulatory drugs, immunosuppressive drugs, interferons, and others. The immunomodulatory drug segment is expected to dominate the global relapsing multiple sclerosis treatment market during the forecast period owing to their ability to modulate or regulate immune system responses. On the basis of application, the global relapsing multiple sclerosis treatment market is segmented into hospital pharmacy, retail pharmacy, and online stores. The hospital pharmacy segment dominates this market due to increased use of these drugs for treating chronic diseases such as MS in hospitals.
Product Definition:
The definition of relapse in relation to multiple sclerosis is a sudden worsening or recurrence of symptoms. This may include a new lesion on an MRI scan. Relapsing MS is the most common form of the disease, affecting around 85% of people with MS.
Immunomodulatory:
Immunomodulatory drugs are used to treat relapsing multiple sclerosis. The main aim of these drugs is to reduce the frequency and severity of attacks by modifying the immune system. These medicines can modify both T cell (Th1, Th2, Th17) as well as B cell functions. Some immunomodulatory agents have effects on only one type of white blood cells (neutrophils/lymphocytes). Others act on both types of white blood cells.
Immunosuppressive:
Immunosuppressive drugs are used to reduce the immune response to a specific target. The main objective of immunosuppressive drug is to reduce the frequency and severity of relapses. Immunosuppressants can be further divided into two categories, namely biologics and non-biologics.
Application Insights:
The global market for relapsing-remitting multiple sclerosis treatment was valued at USD 159.3 million in 2016 and is expected to grow at a CAGR of XX% from 2017 to 2030. Factors such as availability of different treatment options, growing awareness about the disease, and increasing government funding are anticipated to drive the segment growth over the forecast period.
On the other hand, secondary progressive multiple sclerosis treated with glatiramer acetate accounted for a revenue share of 21.1% in 2016 owing to an increase in patients opting for this type of medication due to benefits such as improved mobility.
Regional Analysis:
North America dominated the global market in 2018. The presence of key players, favorable reimbursement policies, and increasing healthcare expenditure are some of the factors contributing to its growth. In addition, growing awareness about multiple sclerosis treatment options is expected to drive demand for these drugs over the forecast period.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income and improving healthcare infrastructure in emerging countries such as China and India.
Key Findings: ‘’) ‘’) ‘’) ‘’) ▬ ) ) ) Key Points To Remember 1.
Growth Factors:
- Increasing incidence of MS
- Growing awareness about MS and its treatment options
- Rising demand for better and more effective therapies for treating MS
- Availability of government funding for research on new MS therapies
- Technological advancements in the field of multiple sclerosis treatment
Scope Of The Report
Report Attributes
Report Details
Report Title
Relapsing Multiple Sclerosis Treatment Market Research Report
By Type
Immunomodulatory, Immunosuppressive, Interferons, Others
By Application
Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027, Hospital Pharmacy, Retail Pharmacy, Online Stores
By Companies
Pfizer, Merck & Co, Teva Pharmaceutical, Sanofi, Bayer, Biogen, Roche, Novartis, CinnaGen, Mylan, Bristol-Myers Squibb, Janssen Pharmaceuticals, Acorda Therapeutics
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
248
Number of Tables & Figures
174
Customization Available
Yes, the report can be customized as per your need.
Global Relapsing Multiple Sclerosis Treatment Market Report Segments:
The global Relapsing Multiple Sclerosis Treatment market is segmented on the basis of:
Types
Immunomodulatory, Immunosuppressive, Interferons, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027, Hospital Pharmacy, Retail Pharmacy, Online Stores
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Pfizer
- Merck & Co
- Teva Pharmaceutical
- Sanofi
- Bayer
- Biogen
- Roche
- Novartis
- CinnaGen
- Mylan
- Bristol-Myers Squibb
- Janssen Pharmaceuticals
- Acorda Therapeutics
Highlights of The Relapsing Multiple Sclerosis Treatment Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Immunomodulatory
- Immunosuppressive
- Interferons
- Others
- By Application:
- Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027
- Hospital Pharmacy
- Retail Pharmacy
- Online Stores
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Relapsing Multiple Sclerosis Treatment Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
There is no one-size-fits-all answer to this question, as the best treatment for relapsing multiple sclerosis will vary depending on the individual's symptoms and overall health. However, some common treatments for relapsing multiple sclerosis include: Physical therapy : Physical therapy may help improve mobility and function in people with relapsing multiple sclerosis. : Physical therapy may help improve mobility and function in people with relapsing multiple sclerosis. Medications : Some medications used to treat other diseases can also be helpful in controlling symptoms of relapsing Multiple Sclerosis. These medications include interferon beta (IFNβ) or glatiramer acetate (GA). IFNβ is typically given as an injection every two weeks, while GA is usually taken by mouth once a day. Side effects of both drugs can be mild but can include flu-like symptoms, muscle aches, fever and weight loss. More serious side effects are rare but possible including heart problems or cancer . It's important to discuss potential side effects with your doctor before starting any medication for MS . : Some medications used to treat other diseases can also be helpful in controlling symptoms of relapsing Multiple Sclerosis. These medications include interferon beta (IFNβ) or glatiramer acetate (GA). IFNβ is typically given as an injection every two weeks, while GA is usually taken by mouth once a day. Side effects of both drugs can be mild but can include flu-like , muscle aches, fever and weight loss. More serious side effects are rare but possible including heart problems or . It's important to discuss potential side effects with your doctor before starting any medication for MS Psychological support: Psychological support may provide relief from stressors that contribute to relapse in people with MS . This type of support includes group sessions led by trained professionals who offer emotional assistance along with practical advice on coping mechanisms such as exercise , diet , sleep hygiene and stress management
Some of the major players in the relapsing multiple sclerosis treatment market are Pfizer, Merck & Co, Teva Pharmaceutical, Sanofi, Bayer, Biogen, Roche, Novartis, CinnaGen, Mylan, Bristol-Myers Squibb, Janssen Pharmaceuticals, Acorda Therapeutics.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Relapsing Multiple Sclerosis Treatment Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Relapsing Multiple Sclerosis Treatment Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Relapsing Multiple Sclerosis Treatment Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Relapsing Multiple Sclerosis Treatment Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Relapsing Multiple Sclerosis Treatment Market Size & Forecast, 2020-2028
4.5.1 Relapsing Multiple Sclerosis Treatment Market Size and Y-o-Y Growth
4.5.2 Relapsing Multiple Sclerosis Treatment Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Immunomodulatory
5.2.2 Immunosuppressive
5.2.3 Interferons
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027
6.2.2 Hospital Pharmacy
6.2.3 Retail Pharmacy
6.2.4 Online Stores
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Relapsing Multiple Sclerosis Treatment Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Relapsing Multiple Sclerosis Treatment Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Immunomodulatory
9.6.2 Immunosuppressive
9.6.3 Interferons
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027
9.10.2 Hospital Pharmacy
9.10.3 Retail Pharmacy
9.10.4 Online Stores
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Immunomodulatory
10.6.2 Immunosuppressive
10.6.3 Interferons
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027
10.10.2 Hospital Pharmacy
10.10.3 Retail Pharmacy
10.10.4 Online Stores
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Immunomodulatory
11.6.2 Immunosuppressive
11.6.3 Interferons
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027
11.10.2 Hospital Pharmacy
11.10.3 Retail Pharmacy
11.10.4 Online Stores
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Immunomodulatory
12.6.2 Immunosuppressive
12.6.3 Interferons
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027
12.10.2 Hospital Pharmacy
12.10.3 Retail Pharmacy
12.10.4 Online Stores
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Immunomodulatory
13.6.2 Immunosuppressive
13.6.3 Interferons
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Global Relapsing Multiple Sclerosis Treatment Market Share by Sales Channel: 2016 VS 2021 VS 2027
13.10.2 Hospital Pharmacy
13.10.3 Retail Pharmacy
13.10.4 Online Stores
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Relapsing Multiple Sclerosis Treatment Market: Competitive Dashboard
14.2 Global Relapsing Multiple Sclerosis Treatment Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Pfizer
14.3.2 Merck & Co
14.3.3 Teva Pharmaceutical
14.3.4 Sanofi
14.3.5 Bayer
14.3.6 Biogen
14.3.7 Roche
14.3.8 Novartis
14.3.9 CinnaGen
14.3.10 Mylan
14.3.11 Bristol-Myers Squibb
14.3.12 Janssen Pharmaceuticals
14.3.13 Acorda Therapeutics
